Journal of The Korean Society of Inherited Metabolic disease (대한유전성대사질환학회지)

The Korea Society of Inherited Metabolic Disease (대한유전성대사질환학회)
권호 표지

The Strategy for Diagnosis and Treatment of Isovaleric Acidemia

아이소발레릭산혈증의 신생아선별검사 후 진단 및 치료 전략

  • Ko, Jung Min (Department of Pediatrics, Seoul National University Children's Hospital) ;
  • Lee, Kyung-A (Department of Laboratory Medicine, Yonsei University College of Medicine)
  • 고정민 (서울대학교 어린이병원 소아청소년과) ;
  • 이경아 (연세대학교 강남세브란스병원 진단검사의학과)
  • Published : 2016.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Isovaleric acidemia (IVA) is an autosomal recessively inherited organic acid disorder due to a defect of the enzyme isovaleryl-CoA dehydrogenase in the leucine metabolic pathway. Deficiency of this enzyme results in the accumulation of derivatives of isovaleryl-CoA. In acute illness in IVA, isovaleric acid and its derivatives accumulate and profound metabolic acidosis with ketosis, characteristic pungent body odor, hypoglycemia, and hyperammonemia can be developed. Additionally, recurrent vomiting, failure to thrive, developmental delay, epilepsy and mental retardation are chronic presenting symptoms and signs for IVA. On the result of newborn screening for inherited metabolic disorders, increased levels of isovalerylcarnitine (C5) are shown. However, C5 elevation can be accompanied with short/branched-chain acyl-CoA dehydrogenase (SBCAD) and therapy with certain antibiotics containing pivalic acid. Quantitative measurement of organic acids in urine and acylcarnitine profiles in plasma are necessary to differential diagnosis. Molecular genetic analysis of the IVD gene for IVA and ACADSB is also helpful to confirm IVA and SBCAD deficiency, respectively. Considering that IVA can be associated with significant morbidity and mortality at acute presentation of metabolic crisis, early diagnosis prior to the onset of symptoms by newborn screening enable to introduction of early treatment and prevention of acute and chronic complications.

IVA는 상염색체 열성의 유전방식을 보이는 leucine 대사 장애 질환이자 대표적인 유기산 혈증이다. IVD 유전자의 돌연변이에 의한 isovaleryl-CoA dehydrogenase 효소의 결핍이 질환 발생의 원인이다. Isovaleryl-CoA dehydrogenase 효소가 결핍되면 isovaleryl-CoA의 대사물질이 비정상적으로 체내에 축적되어 대사성 산증 및 고암모니아혈증 등의 급성 대사성 위기와 발달지연, 성장지연, 및 경련성질환 등의 만성 합병증을 초래할 수 있기 때문에, 급성 대사성 위기 및 만성합병증의 발생을 예방하기 위해 조기 진단에 따른 적절한 치료의 도입이 중요하다. 현재 IVA은 국내에서 시행되는 탠덤 매스 스크리닝법을 이용한 신생아 대사질환 선별검사 항목에 포함되어 있으며, C5의 상승으로 의심할 수 있다. 그러나 SBCAD 결핍증 혹은 pivalic acid 유래물이 포함된 항생제를 투여한 경우에도 C5의 상승이 동반될 수 있기 때문에, 감별진단 및 확진을 위한 추가적인 생화학적, 유전학적 검사가 필수적이다.

Keywords

References

  1. Vockley J, Ensenauer R. Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. Am J Med Genet C Semin Med Genet 2006;142C:95-103. https://doi.org/10.1002/ajmg.c.30089
  2. Sass JO, Ensenauer R, Roschinger W, Reich H, Steuerwald U, Schirrmacher O, et al. 2-Methylbutyryl-coenzyme A dehydrogenase deficiency: functional and molecular studies on a defect in isoleucine catabolism. Mol Genet Metab 2008;93:30-5.
  3. Parimoo B, Tanaka K. Structural organization of the human isovaleryl-CoA dehydrogenase gene. Genomics 1993;15:582-90. https://doi.org/10.1006/geno.1993.1111
  4. Arden KC, Viars CS, Fu K, Rozen R. Localization of short/branched chain acyl-CoA dehydrogenase (ACA DSB) to human chromosome 10. Genomics 1995;25:743-5. https://doi.org/10.1016/0888-7543(95)80023-F
  5. Orphanet. http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=33.
  6. Ensenauer R, Fingerhut R, Maier EM, Polanetz R, Olgemoller B, Roschinger W, et al. Newborn screening for isovaleric acidemia using tandem mass spectrometry: data from 1.6 million newborns. Clin Chem 2011;57:623-6. https://doi.org/10.1373/clinchem.2010.151134
  7. Newborn Screening ACT Sheets and Confirmatory Algorithms. http://www.ncbi.nlm.nih.gov/books/NBK55827/.
  8. Andresen BS, Christensen E, Corydon TJ, Bross P, Pilgaard B, Wanders RJ, et al. Isolated 2-methylbutyrylglycinuria caused by short/branched-chain acyl-CoA dehydrogenase deficiency: identification of a new enzyme defect, resolution of its molecular basis, and evidence for distinct acyl-CoA dehydrogenases in isoleucine and valine metabolism. Am J Hum Genet 2000;67:1095-103. https://doi.org/10.1086/303105
  9. Abdenur JE, Chamoles NA, Guinle AE, Schenone AB, Fuertes AN. Diagnosis of isovaleric acidaemia by tandem mass spectrometry: false positive result due to pivaloylcarnitine in a newborn screening programme. J Inherit Metab Dis 1998;21:624-30. https://doi.org/10.1023/A:1005424331822
  10. Dixon MA, Leonard JV. Intercurrent illness in inborn errors of intermediary metabolism. Arch Dis Child 1992;67:1387-91. https://doi.org/10.1136/adc.67.11.1387
  11. Morris AA, Leonard JV. Early recognition of metabolic decompensation. Arch Dis Child 1997;76:555-6. https://doi.org/10.1136/adc.76.6.555
  12. Daniotti M, la Marca G, Fiorini P, Filippi L. New developments in the treatment of hyperammonemia: emerging use of carglumic acid. Int J Gen Med 2011;4:21-8.
  13. Sweetman L. Newborn screening by tandem mass spectrometry: gaining experience. Clin Chem 2001;47:1937-8.
  14. Harris RA, Joshi M, Jeoung NH. Mechanisms responsible for regulation of branched-chain amino acid catabolism. Biochem Biophys Res Commun 2004;313:391-6. https://doi.org/10.1016/j.bbrc.2003.11.007
  15. Shigematsu Y, Sudo M, Momoi T, Inoue Y, Suzuki Y, Kameyama J. Changing plasma and urinary organic acid levels in a patient with isovaleric acidemia during an attack. Pediatr Res 1982;16:771-5. https://doi.org/10.1203/00006450-198209000-00013
  16. Elsas LJ, 2nd, Naglak M. Acute and chronic-intermittent isovaleric acidemia: diagnosis and glycine therapy. Acta Paediatr Jpn 1988;30:442-51. https://doi.org/10.1111/j.1442-200X.1988.tb02535.x
  17. Fries MH, Rinaldo P, Schmidt-Sommerfeld E, Jurecki E, Packman S. Isovaleric acidemia: response to a leucine load after three weeks of supplementation with glycine, L-carnitine, and combined glycine-carnitine therapy. J Pediatr 1996;129:449-52. https://doi.org/10.1016/S0022-3476(96)70081-1